Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Technology
Share your love
Meeting expectations with evolving technology
(Image Credit: AdobeStock) As an ophthalmology resident, I am increasingly meeting patients who underwent LASIK surgery 15 or 20 years ago. They were the early adopters of refractive surgery, thrilled to toss their glasses in their youth. Now in their…
Post-LASIK presbyopia: Meeting expectations with evolving technology – Ophthalmology Times
Post-LASIK presbyopia: Meeting expectations with evolving technology Ophthalmology Times Source: Author: | Date: 2025-08-26 10:07:00 Source: Author: | Date: 2025-08-26 10:07:00
The potential of AI in retina with Daniela Ferrara
This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…
Alcon presenting at APACRS 2025
(Image credit: ©RealityImages/AdobeStock) Alcon announced presentations during the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone booth.1 APACRS…
Study establishes reference data set for geographic atrophy lesion progression
(Image Credit: AdobeStock/tadamichi) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science &…
Artificial intelligence technology in ophthalmology public health: current applications and future directions – Frontiers
Artificial intelligence technology in ophthalmology public health: current applications and future directions Frontiers Source: Author: | Date: 2025-03-28 20:13:00 Source: Author: | Date: 2025-03-28 20:13:00
4DMT Reveals Preclinical Data on TVE Platform
4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the capabilities of its Therapeutic Vector Evolution (TVE) platform. The research focuses on the intravitreal R100 vector and the R100-based genetic medicine 4D-150. This groundbreaking study, titled “Design…
FDA Clears ViGeneron’s VG801 for Stargardt Disease
The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for VG801, ViGeneron’s novel gene therapy candidate designed to treat Stargardt disease and other retinal dystrophies caused by mutations in the ABCA4 gene. This marks…
2023 Recap: Top 15 Research in Ophthalmology
2024 Recap is here! Click to review:Top 10 Breakthroughs in Ophthalmology Research In the fast-evolving landscape of ophthalmology research, 2023 has proven to be a pivotal year marked by groundbreaking discoveries and innovation. From revolutionary cell replacement therapies to novel…
Atsena Completes XLRS Gene Therapy Trial Dosing
Atsena Therapeutics has successfully completed dosing in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal delivery of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study represents an important step forward in developing…